From Wikipedia, the free encyclopedia
Stamulumab (MYO-029[1]) is an experimental myostatin inhibiting drug developed by Wyeth Pharmaceuticals for the treatment of muscular dystrophy. MYO-029 was formulated and tested by Wyeth in Collegeville, Pennsylvania.[2] Myostatin is a protein that inhibits the growth of muscle tissue, MYO-029 is a recombinant human antibody designed to bind to and inhibit the activity of myostatin.[3]
Stamulumab is a G1 immunoglobulin antibody which binds to myostatin and prevents it from binding to its target site, thus inhibiting the growth-limiting action of myostatin on muscle tissue. Research completed in 2002 found that Stamulumab might one day prove to be an effective treatment for Duchenne muscular dystrophy[4]
[edit] Phase 1 and 2 Trials
- Wyeth undertook a Phase 1 and 2 clinical trial in 2005 and 2006 of MY0-029. The multiple ascending dose trial (36 patients per cohort) contained some measures of efficacy. The trial's participants included people afflicted with Facioscapulohumeral muscular dystrophy, Becker's muscular dystrophy, and Limb-girdle muscular dystrophy. Through 2007 Wyeth has been analyzing the results but the hoped-for news and/or a publication in 2007 did not occur. [2][5][6]. However, as of January 24, 2008, the study has been accepted by a peer-reviewed journal and publication is expected "in the next few months.... publication is there now, it shows no success!!"[7]
[edit] Related
- ACVR2B is similar to Stamulumab but is not an antibody; rather, it provides a portion of the molecule to which myostatin would normally bind thus preventing the myostatin from binding with the actual molecule[8].
[edit] References
- ^ Wyeth Product Pipeline, Wyeth, Website accessed April 22, 2007
- ^ a b NIH's ClinicalTrials.gov, Study Evaluating MYO-029 in Adult Muscular Dystrophy, record last updated January 24, 2007
- ^ medicalnewstoday.com, Wyeth Initiates Clinical Trial with Investigational Muscular Dystrophy Therapy MYO-029, Article Date: 28 Feb 2005 - 7:00 PDT
- ^ Blocking Myostatin Proves Beneficial in Mice with DMD, MDA Research News, 11/27/2002
- ^ Wyeth Analyzing MYO-029 Results, Muscular Dystrophy Association announcement, December 4, 2006
- ^ FSH Watch Newsletter, pg 11, FSH Society, Summer 2007
- ^ Pharma Company Responds to WiSci on Muscle-Building Drug, Wired Science, Alexis Madrigal, January 24, 2008, 2008, 4:26:27 PM
- ^ New Myostatin Blocker Makes Mouse Muscles 60 Percent Larger, MDA Research News, January 6, 2006
|
Human monoclonal antibodies ("-u-") |
|
| "-limu-" (immune system) |
|
|
| "-kinu-" (interleukin as target) |
|
|
| "-tumu-" (cancer immunotherapy) |
Adecatumumab, Anetumumab, Belimumab, Duntumumab, Iratumumab, Lexatumumab, Lucatumumab, Mapatumumab, Ofatumumab, Panitumumab, Pritumumab, Votumumab, Zalutumumab, Zanolimumab
|
|
| "-osu-" (bone) |
|
|
| "-mulu-" (musculoskeletal) |
|
|
| "-fungu-" (fungal) |
|
|
| "-viru-" (viral) |
|
|
| "-bacu-" (bacterial) |
|
|
|
Muscular Dystrophy |
|
| The Nine Primary Muscular Dystrophies |
|
|
|
Related topics
|
|
| National/International Organizations |
|
|
| US government Institutes and Legislation |
|
|
| National/International Events |
|
|
| Recent or Ongoing Clinical Trials |
Stamulumab (MYO-029)
|
|
